Strategic Merger Stelis Biopharma recently merged with SteriScience and Strides to form OneSource Specialty, signaling a larger, more integrated CDMO capacity and potential cross-sell opportunities across now-expanded manufacturing capabilities for biologics.

Integrated CDMO Offering As a fully integrated biopharma CDMO with end-to-end capabilities from cell line development to fill/finish, target customers seeking single-vendor solutions for complex biologic programs and faster time to market.

Bengaluru Footprint Strategic location in Bengaluru, India positions Stelis to leverage regional R&D and next-gen manufacturing ecosystems, appealing to global biologics clients seeking cost efficiencies and access to Asia-Pacific manufacturing hubs.

Financing & Growth With a Series C in 2021 totaling $125M and total funding of $230M, plus revenue in the mid-range of $25–$50M suggests capacity for scale investments, partnerships, and co-development opportunities with financially backed clients.

Expansion Activity Historical facility expansions and divestments (Unit 3 sale, continued growth at Unit 2) indicate ongoing capacity management and willingness to restructure to align with client mix, enabling targeted upsell of new drug substance and drug product programs.